TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transdermal Nicotine and Bupropion-SR in Schizophrenics (Study 2)
Brief Summary: Many individuals with schizophrenia smoke cigarettes but little is known about the factors that control smoking in people with schizophrenia. The purpose of this trial is to evaluate how bupropion, an antidepressant medication, affects smoking behaviors in individuals with schizophrenia who smoke.


Options:
A: Arm Label: Order 1; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Arm Label: Order 2; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Arm Label: Order 3; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Arm Label: Order 4; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Intervention Type: DRUG; Name: Nicotine Nasal Spray; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4 | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4 | Intervention Type: DRUG; Name: Placebo Nasal Spray; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4 | Intervention Type: DRUG; Name: Placebo Varenicline; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: 300 mg/day bupropion-sr | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0 mg/day bupropion-sr | Intervention Type: DRUG; Name: 300 mg/day bupropion-sr; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 0 mg/day bupropion-sr; Assigned to Arm(s): 2
C: Arm Label: Selegiline Transdermal Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Selegiline Transdermal Patch, Behavioral: Smoking Cessation Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Smoking Cessation Counseling | Intervention Type: DRUG; Name: Selegiline Transdermal Patch; Assigned to Arm(s): Selegiline Transdermal Patch | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Smoking Cessation Counseling; Assigned to Arm(s): Placebo, Selegiline Transdermal Patch
D: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transdermal Nicotine and Bupropion-SR in Schizophrenics (Study 2)
Brief Summary: Many individuals with schizophrenia smoke cigarettes but little is known about the factors that control smoking in people with schizophrenia. The purpose of this trial is to evaluate how bupropion, an antidepressant medication, affects smoking behaviors in individuals with schizophrenia who smoke.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: nicotine transdermal patch | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine transdermal patch | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: nicotine transdermal patch; Assigned to Arm(s): 1, 2
B: Arm Label: Scheduled Gradual Reduction + Varenicline; Type: EXPERIMENTAL; Interventions: Other: Scheduled Gradual Reduction + Varenicline | Arm Label: Scheduled Gradual Reduction + Placebo Drug; Type: EXPERIMENTAL; Interventions: Other: Scheduled Gradual Reduction + Placebo Drug | Arm Label: Basic Advice + Varenicline; Type: EXPERIMENTAL; Interventions: Other: Basic Advice + Varenicline | Arm Label: Basic Advice + Placebo Drug; Type: PLACEBO_COMPARATOR; Interventions: Other: Basic Advice + Placebo Drug | Intervention Type: OTHER; Name: Scheduled Gradual Reduction + Varenicline; Assigned to Arm(s): Scheduled Gradual Reduction + Varenicline | Intervention Type: OTHER; Name: Scheduled Gradual Reduction + Placebo Drug; Assigned to Arm(s): Scheduled Gradual Reduction + Placebo Drug | Intervention Type: OTHER; Name: Basic Advice + Varenicline; Assigned to Arm(s): Basic Advice + Varenicline | Intervention Type: OTHER; Name: Basic Advice + Placebo Drug; Assigned to Arm(s): Basic Advice + Placebo Drug
C: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Bupropion | Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: 300 mg/day bupropion-sr | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0 mg/day bupropion-sr | Intervention Type: DRUG; Name: 300 mg/day bupropion-sr; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 0 mg/day bupropion-sr; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transdermal Nicotine and Bupropion-SR in Schizophrenics (Study 2)
Brief Summary: Many individuals with schizophrenia smoke cigarettes but little is known about the factors that control smoking in people with schizophrenia. The purpose of this trial is to evaluate how bupropion, an antidepressant medication, affects smoking behaviors in individuals with schizophrenia who smoke.


Options:
A: Intervention Type: DRUG; Name: bupropion (Wellbutrin); Assigned to Arm(s): N/A
B: Arm Label: Varenicline + Active Tailored Dose; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline + Placebo Tailored Dose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Varenicline + Placebo Tailored Dose | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose, Varenicline + Placebo Tailored Dose
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: 300 mg/day bupropion-sr | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0 mg/day bupropion-sr | Intervention Type: DRUG; Name: 300 mg/day bupropion-sr; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 0 mg/day bupropion-sr; Assigned to Arm(s): 2
D: Arm Label: Extended Brief Contact; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Initial Individual counseling, Behavioral: Check-ins with medical staff | Arm Label: Extended Health Education; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Initial Individual counseling, Behavioral: Extended Individual Counseling - Health Model | Arm Label: Extended Relapse Prevention plus varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Initial Individual counseling, Behavioral: Extended Individual Counseling - Relapse Prevention Model | Arm Label: Extended Relapse Prevention; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Initial Individual counseling, Behavioral: Extended Individual Counseling - Relapse Prevention Model | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Extended Brief Contact, Extended Health Education, Extended Relapse Prevention, Extended Relapse Prevention plus varenicline | Intervention Type: BEHAVIORAL; Name: Initial Individual counseling; Assigned to Arm(s): Extended Brief Contact, Extended Health Education, Extended Relapse Prevention, Extended Relapse Prevention plus varenicline | Intervention Type: BEHAVIORAL; Name: Check-ins with medical staff; Assigned to Arm(s): Extended Brief Contact | Intervention Type: BEHAVIORAL; Name: Extended Individual Counseling - Health Model; Assigned to Arm(s): Extended Health Education | Intervention Type: BEHAVIORAL; Name: Extended Individual Counseling - Relapse Prevention Model; Assigned to Arm(s): Extended Relapse Prevention, Extended Relapse Prevention plus varenicline

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CBT for Depression & Adherence in HIV Methadone Patients
Brief Summary: Patients with HIV, depression, and opioid-dependence are at high risk for poor health outcomes. This is a two-arm randomized controlled trial of cognitive-behavioral therapy for depression and HIV medication adherence in patients with opioid dependence who are receiving methadone maintenance treatment. The project is based on our pilot work with close attention to NIDA guidelines for a staged approach to treatment development and testing (Rounsaville et al., 2001).

Depression is highly comorbid with both HIV infection and with opioid dependence. Depression and substance abuse are both associated with poor adherence to antiretroviral medications. Patients with HIV, depression, and opioid dependence are at high risk for poor health outcomes. Cognitive-behavioral therapy is the most widely studied and efficacious psychosocial intervention for depression; and research by the PI and others has shown that cognitive-behavioral interventions have been successful in promoting adherence to HIV medications.


Options:
A: Arm Label: Family Function Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Familias Unidas | Arm Label: Treatment as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Familias Unidas; Assigned to Arm(s): Family Function Intervention
B: Arm Label: 1-Day MBSR; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: MBSR | Arm Label: 8-week MBSR; Type: EXPERIMENTAL; Interventions: Behavioral: MBSR | Intervention Type: BEHAVIORAL; Name: MBSR; Assigned to Arm(s): 1-Day MBSR, 8-week MBSR
C: Arm Label: Mentor Mothers Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Peer support and mentoring | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Peer support and mentoring; Assigned to Arm(s): Mentor Mothers Intervention
D: Arm Label: CBT-AD; Type: EXPERIMENTAL; Interventions: Behavioral: CBT-AD | Arm Label: ETAU; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ETAU | Intervention Type: BEHAVIORAL; Name: CBT-AD; Assigned to Arm(s): CBT-AD | Intervention Type: BEHAVIORAL; Name: ETAU; Assigned to Arm(s): ETAU

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CBT for Depression & Adherence in HIV Methadone Patients
Brief Summary: Patients with HIV, depression, and opioid-dependence are at high risk for poor health outcomes. This is a two-arm randomized controlled trial of cognitive-behavioral therapy for depression and HIV medication adherence in patients with opioid dependence who are receiving methadone maintenance treatment. The project is based on our pilot work with close attention to NIDA guidelines for a staged approach to treatment development and testing (Rounsaville et al., 2001).

Depression is highly comorbid with both HIV infection and with opioid dependence. Depression and substance abuse are both associated with poor adherence to antiretroviral medications. Patients with HIV, depression, and opioid dependence are at high risk for poor health outcomes. Cognitive-behavioral therapy is the most widely studied and efficacious psychosocial intervention for depression; and research by the PI and others has shown that cognitive-behavioral interventions have been successful in promoting adherence to HIV medications.


Options:
A: Arm Label: Integrated treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated mental health and substance use treatment | Arm Label: Treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Intervention Type: BEHAVIORAL; Name: Integrated mental health and substance use treatment; Assigned to Arm(s): Integrated treatment | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): Treatment as usual
B: Arm Label: Integrated care; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated care | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Integrated care; Assigned to Arm(s): Integrated care | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual care
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Contingency Management | Arm Label: 2; Type: OTHER; Interventions: Behavioral: Non Contingent Control Condition | Intervention Type: BEHAVIORAL; Name: Contingency Management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Non Contingent Control Condition; Assigned to Arm(s): 2
D: Arm Label: CBT-AD; Type: EXPERIMENTAL; Interventions: Behavioral: CBT-AD | Arm Label: ETAU; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ETAU | Intervention Type: BEHAVIORAL; Name: CBT-AD; Assigned to Arm(s): CBT-AD | Intervention Type: BEHAVIORAL; Name: ETAU; Assigned to Arm(s): ETAU

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Selegiline Patch for Treatment of Nicotine Dependence
Brief Summary: Relapse to smoking is a common problem affecting smokers who seek treatment. The purpose of this study is examine whether selegiline, given in the form of a skin patch, is effective in stopping smoking.


Options:
A: Arm Label: Scheduled Gradual Reduction + Varenicline; Type: EXPERIMENTAL; Interventions: Other: Scheduled Gradual Reduction + Varenicline | Arm Label: Scheduled Gradual Reduction + Placebo Drug; Type: EXPERIMENTAL; Interventions: Other: Scheduled Gradual Reduction + Placebo Drug | Arm Label: Basic Advice + Varenicline; Type: EXPERIMENTAL; Interventions: Other: Basic Advice + Varenicline | Arm Label: Basic Advice + Placebo Drug; Type: PLACEBO_COMPARATOR; Interventions: Other: Basic Advice + Placebo Drug | Intervention Type: OTHER; Name: Scheduled Gradual Reduction + Varenicline; Assigned to Arm(s): Scheduled Gradual Reduction + Varenicline | Intervention Type: OTHER; Name: Scheduled Gradual Reduction + Placebo Drug; Assigned to Arm(s): Scheduled Gradual Reduction + Placebo Drug | Intervention Type: OTHER; Name: Basic Advice + Varenicline; Assigned to Arm(s): Basic Advice + Varenicline | Intervention Type: OTHER; Name: Basic Advice + Placebo Drug; Assigned to Arm(s): Basic Advice + Placebo Drug
B: Arm Label: Varenicline + Active Tailored Dose; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline + Placebo Tailored Dose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Varenicline + Placebo Tailored Dose | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose, Varenicline + Placebo Tailored Dose
C: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Drug Selegiline; Type: EXPERIMENTAL; Interventions: Drug: Selegiline | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: matching placebo | Intervention Type: DRUG; Name: Selegiline; Assigned to Arm(s): Drug Selegiline | Intervention Type: OTHER; Name: matching placebo; Assigned to Arm(s): Matching placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Selegiline Patch for Treatment of Nicotine Dependence
Brief Summary: Relapse to smoking is a common problem affecting smokers who seek treatment. The purpose of this study is examine whether selegiline, given in the form of a skin patch, is effective in stopping smoking.


Options:
A: Arm Label: Drug Selegiline; Type: EXPERIMENTAL; Interventions: Drug: Selegiline | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: matching placebo | Intervention Type: DRUG; Name: Selegiline; Assigned to Arm(s): Drug Selegiline | Intervention Type: OTHER; Name: matching placebo; Assigned to Arm(s): Matching placebo
B: Arm Label: varenicline and buproprion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: bupropion SR | Arm Label: varenicline and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline and buproprion SR, varenicline and placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): varenicline and placebo | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): varenicline and buproprion SR
C: Arm Label: Effectiveness of Nicotine patch only; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Arm Label: Effectiveness of Combination NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine lozenge, Drug: Nicotine Patch | Arm Label: Effectiveness of Varenicline [Chantix]; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Effectiveness of Varenicline [Chantix] | Intervention Type: DRUG; Name: Nicotine lozenge; Assigned to Arm(s): Effectiveness of Combination NRT | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Effectiveness of Combination NRT, Effectiveness of Nicotine patch only
D: Arm Label: Order 1; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Arm Label: Order 2; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Arm Label: Order 3; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Arm Label: Order 4; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Intervention Type: DRUG; Name: Nicotine Nasal Spray; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4 | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4 | Intervention Type: DRUG; Name: Placebo Nasal Spray; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4 | Intervention Type: DRUG; Name: Placebo Varenicline; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Selegiline Patch for Treatment of Nicotine Dependence
Brief Summary: Relapse to smoking is a common problem affecting smokers who seek treatment. The purpose of this study is examine whether selegiline, given in the form of a skin patch, is effective in stopping smoking.


Options:
A: Arm Label: Sugar Pill; Type: PLACEBO_COMPARATOR; Interventions: Other: Sugar Pill | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Bupropion HCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl | Intervention Type: OTHER; Name: Sugar Pill; Assigned to Arm(s): Sugar Pill | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Bupropion HCl; Assigned to Arm(s): Bupropion HCl
B: Arm Label: Drug Selegiline; Type: EXPERIMENTAL; Interventions: Drug: Selegiline | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: matching placebo | Intervention Type: DRUG; Name: Selegiline; Assigned to Arm(s): Drug Selegiline | Intervention Type: OTHER; Name: matching placebo; Assigned to Arm(s): Matching placebo
C: Arm Label: Arm I (varenicline); Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Arm II (nicotine patch); Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine patch | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Arm I (varenicline) | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): Arm II (nicotine patch)
D: Intervention Type: DRUG; Name: bupropion SR (sustained-release); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Selegiline Patch for Treatment of Nicotine Dependence
Brief Summary: Relapse to smoking is a common problem affecting smokers who seek treatment. The purpose of this study is examine whether selegiline, given in the form of a skin patch, is effective in stopping smoking.


Options:
A: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Arm Label: P; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl ER | Intervention Type: DRUG; Name: Bupropion HCl ER; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): P
D: Arm Label: Drug Selegiline; Type: EXPERIMENTAL; Interventions: Drug: Selegiline | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: matching placebo | Intervention Type: DRUG; Name: Selegiline; Assigned to Arm(s): Drug Selegiline | Intervention Type: OTHER; Name: matching placebo; Assigned to Arm(s): Matching placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cognitive Therapy for Suicide Attempters With Drug Dependence Disorder
Brief Summary: This study will examine the effectiveness of combining cognitive therapy with enriched usual care for preventing subsequent suicide attempts in people with a drug dependence who have recently attempted suicide.


Options:
A: Arm Label: Naltrexone-Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Naltrexone, Drug: Placebo | Arm Label: Placebo-Naltrexone; Type: PLACEBO_COMPARATOR; Interventions: Drug: Naltrexone, Drug: Placebo | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): Naltrexone-Placebo, Placebo-Naltrexone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Naltrexone-Placebo, Placebo-Naltrexone
B: Arm Label: Cognitive Therapy; Type: OTHER; Interventions: Behavioral: Cognitive Therapy | Arm Label: Enriched Care; Type: OTHER; Interventions: Other: Enriched Care | Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): Cognitive Therapy | Intervention Type: OTHER; Name: Enriched Care; Assigned to Arm(s): Enriched Care
C: Arm Label: Commitment; Type: EXPERIMENTAL; Interventions: Behavioral: DBT Skills Training | Arm Label: Psychoeducation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DBT Skills Training | Intervention Type: BEHAVIORAL; Name: DBT Skills Training; Assigned to Arm(s): Commitment, Psychoeducation
D: Arm Label: Care Management; Type: EXPERIMENTAL; Interventions: Behavioral: Care Management | Arm Label: Skills Training; Type: EXPERIMENTAL; Interventions: Behavioral: Skills Training | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Care Management; Assigned to Arm(s): Care Management | Intervention Type: BEHAVIORAL; Name: Skills Training; Assigned to Arm(s): Skills Training | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care

Answer: B